ArticleVirchows Archiv : an international journal of pathology2005
Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction.
Article in Virchows Archiv : an international journal of pathology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01704690 (Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer), which is not on this map. Cited by 85 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer
Who cites it
85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 333 citations in OpenAlex.
- Minimally invasive surgery for esophageal cancer: a review on sentinel node concept.Surgical endoscopy · 2014Pooled it
- Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.World journal of gastroenterology · 2013Pooled it
- The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review.The American journal of gastroenterology · 2012Pooled it
- Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer.Annals of surgical oncology · 2012Trial
- Endoscopic Therapy in Barrett's Esophagus.Visceral medicine · 2026Article
- Endoscopic Submucosal Dissection (ESD) of Upper Gastrointestinal Carcinomas: An Integrated Clinical and Pathological Perspective.Journal of clinical medicine · 2025Review
- Outcomes after radical endoscopic resection of high risk T1 esophageal adenocarcinoma: an international multicenter retrospective cohort study.Endoscopy · 2025Article
- Reassessment reveals underestimation of infiltration depth in surgical resection specimens with lymph-node positive T1b esophageal adenocarcinoma.Endoscopy international open · 2025Article
- Management of early oesophageal cancer: An overview.World journal of gastrointestinal surgery · 2024Article
- Management of Esophago-Gastric Junction Carcinoma: A Narrative Multidisciplinary Review.Cancers · 2023Review
- Today's Mistakes and Tomorrow's Wisdom… in the Management of T1b Barrett's Adenocarcinoma.Visceral medicine · 2022Review
- Today's Mistakes and Tomorrow's Wisdom in the Surgical Treatment of Barrett's Adenocarcinoma.Visceral medicine · 2022Review
- Barrett's esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies.World journal of gastrointestinal oncology · 2022Review
- [Treatment recommendations for early esophageal cancer : Endoscopic and surgical options].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2021Review
- Endoscopic resection of Barrett's adenocarcinoma: Intramucosal and low-risk tumours are not associated with lymph node metastases.United European gastroenterology journal · 2021Article
- Comparing long-term outcomes between endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) for type II esophagogastric junction neoplasm.Annals of translational medicine · 2021Article
- Comparisons between minimally invasive and open esophagectomy for esophageal cancer with cervical anastomosis: a retrospective study.Journal of cardiothoracic surgery · 2020Article
- Pathological assessment of endoscopic resections of the gastrointestinal tract: a comprehensive clinicopathologic review.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Review
- Barrett's adenocarcinoma with esophageal varices successfully treated by endoscopic submucosal dissection with direct varices coagulation.Clinical journal of gastroenterology · 2020Article
- Infiltration Depth is the Most Relevant Risk Factor for Overall Metastases in Early Esophageal Adenocarcinoma.World journal of surgery · 2020Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenocarcinoma of the esophagus, or GEJ, has a poor prognosis. Early lesions [i.e. high grade dysplasia (HGD) or T1-carcinoma] are potentially curable. Local endoscopic therapies are promising treatment options for superficial lesions; however, for deeper lesions, surgical resection is considered to be the treatment of choice. To contribute to therapeutic decision-making, we retrospectively analysed the outcome of transhiatal esophagectomy in 120 patients with pathologically proven HGD (n=13) or T1-adenocarcinoma (n=107) of the distal esophagus or gastro-esophageal junction (GEJ). Tumors were subdivided into six different depths of invasion ('T1-mucosal' m1-m3, 'T1-submucosal' sm1-sm3), and the frequency of lymphatic dissemination and time to locoregional and/or distant recurrence were analysed. Only one of the 79 T1m1-3/sm1 tumors (1%) showed lymph node metastases as compared with 18 out of 41 T1sm2-3 tumors (44%). There was a significant difference in recurrence-free period between T1m1-m3/sm1 versus T1sm2-sm3 tumor patients (P log rank <0.0001), with 5-year recurrence-free percentages of 97% and 57%, respectively. In multivariate analysis including age, gender, tumor differentiation grade, N-stage and depth of invasion, only N-stage was an independent prognostic factor for recurrence-free period (hazard rate=5.9, 95% CI 1.7-20.7). However, if N-stage was excluded from analysis, only depth of invasion (T1sm2-3 versus T1m1-m3/sm1) was an independent prognostic factor for recurrence-free period (hazard rate=7.5, 95% CI 2.0-27.7). These data indicate that T1m1-m3/sm1 adenocarcinomas of esophagus or GEJ show a very low risk of lymphatic dissemination and are therefore eligible for local endoscopic therapy. After transhiatal surgical resection, almost half of the patients with T1sm2-sm3 lesions develop recurrent disease within 5 years, and therefore need additional therapy to improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.